Arjona Ferreira Juan Camilo 4
4 · Organon & Co. · Filed Apr 2, 2026
Research Summary
AI-generated summary of this filing
Organon (OGN) CMO Juan Camilo Arjona Receives RSU Award
What Happened
Juan Camilo Arjona Ferreira, Organon & Co.'s Head of R&D and Chief Medical Officer, received a grant of 200,333 restricted stock units (RSUs) on March 31, 2026. At the same time, 13,431 previously granted RSUs vested and were converted into shares. To cover tax withholding on the vested shares, 4,820 shares were surrendered at an effective price of $5.70 per share, generating $27,474 in withheld taxes.
Key Details
- Transaction date: March 31, 2026; Form 4 filed April 2, 2026. No late-filing indication in the provided report.
- New grant: 200,333 RSUs (each RSU = right to 1 share). These RSUs vest in three equal installments: Mar 31, 2027; Mar 31, 2028; Mar 31, 2029. (Footnotes F2, F3)
- Vested conversion: 13,431 RSUs converted to shares (exercise/conversion code M).
- Tax withholding: 4,820 shares withheld/disposed to satisfy tax liability at $5.70/share = $27,474 (code F). Price per share reflects Organon's closing market price on March 30, 2026 (Footnote F1).
- Prior grant context: 40,295 RSUs granted on Mar 31, 2025; one-third of that grant vested on Mar 31, 2026 (Footnote F4).
- Amount owned following the transactions is not specified in the provided excerpt.
Context
This filing reflects typical equity compensation activity: new RSU awards and the vesting/conversion of previously granted RSUs with shares withheld for taxes. These are not open-market purchases or sales of shares by the insider and therefore do not necessarily signal a trading view — they document compensation and standard tax withholding.
Insider Transaction Report
- Exercise/Conversion
Common Stock
2026-03-31+13,431→ 34,867.477 total - Tax Payment
Common Stock
[F1]2026-03-31$5.70/sh−4,820$27,474→ 30,047.477 total - Award
Restricted Stock Units
[F2]2026-03-31+200,333→ 200,333 total→ Common Stock (200,333 underlying) - Exercise/Conversion
Restricted Stock Units
[F3][F4]2026-03-31−13,431→ 26,864 total→ Common Stock (13,431 underlying)
Footnotes (4)
- [F1]The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.
- [F2]On March 31, 2026, the Reporting Person was granted 200,333 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
- [F3]Each RSU represents a contingent right to receive one share of Organon common stock.
- [F4]On March 31, 2025, the Reporting Person was granted 40,295 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028.